GlassScriptPhysician profile
James C Montgomery
NPI 1568476182
$6,187.76
in general payments reported to CMS, 2019-2025
25 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,134 · 2022: $1,210 · 2023: $667 · 2024: $1,139 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.39 |
| Education | $167.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,056.46 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $896.46 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $801.29 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Genzyme Corporation | $563.64 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $554.24 | 2021-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $405.10 | 2021-2022 | |
| Grifols USA, LLC | $354.68 | 2021-2025 | Xembify |
| Genentech USA, INC. | $290.32 | 2021-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $210.93 | 2022-2025 | |
| Kaleo, INC. | $208.83 | 2021-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $112.48 | 2025 | |
| Hospira, INC. | $105.66 | 2021 | |
| Amgen INC. | $96.52 | 2024-2025 | Tezspire |
| Pfizer INC. | $84.62 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $75.16 | 2021-2025 | Orladeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $68.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.50 | 2021-2025 | Glassia, Takhzyro |
| Alk-Abello, INC | $41.47 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $40.48 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $22.98 | 2025 | Dawnzera |
| Lilly USA, LLC | $20.52 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $18.90 | 2024 | Ryaltris |
| Blueprint Medicines Corporation | $17.48 | 2025 | Ayvakit |
| Pharming Healthcare, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.